Home > Insider Trading > Filing (0001104659-20-097233)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1609550	Inspire Medical Systems Inc.	INSP	Surgical & Medical Instruments & Apparatus (3841)	261377674

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1737203	Steven Jandrich	C/O Inspire Medical Systems, Inc. 5500 Wayzata Blvd., Suite 1600 Golden Valley MN 55416	Chief Comp Off & Vp, Human Res	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-08-18	2,013	$42.15	3,818	No	4	M	Direct
Common Stock	Acquisiton	2020-08-18	987	$10.38	4,805	No	4	M	Direct
Common Stock	Disposition	2020-08-18	3,000	$110.00	1,805	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-08-18	2,013	$0.00	2,013	$42.15
Common Stock	Stock Option (Right to Buy)	Disposition	2020-08-18	987	$0.00	987	$10.38

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
22,987		2028-12-18	No	4	M	Direct
6,531		2028-04-09	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	350	Indirect	By son
Common Stock	350	Indirect	By daughter

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The option vested and became exercisable as to 25% of the original 25,000 underlying shares on December 18, 2019 and the remaining 75% of the underlying shares have vested or will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
The option vested and became exercisable as to 25% of the original 7,518 underlying shares on April 9, 2019 and the remaining 75% of the underlying shares have vested or will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.